What is in this vial?

10 mg of TB-500 and 10 mg of BPC-157, lyophilised together — 20 mg of combined material in a fixed 1:1 ratio. The two peptides are unrelated molecules studied in overlapping tissue-repair models.

How much bacteriostatic water suits a 20 mg combined vial?

Laboratory practice typically dissolves the combined vial in 3 ml of bacteriostatic water, giving roughly 6.67 mg/ml of total peptide — about 3.33 mg/ml of each component. The reconstitution calculator on this page converts any water volume and combined dose into exact syringe units and shows the per-component split.

What dose ranges appear in the research?

The literature reports the two peptides separately: BPC-157 protocols centre on 200–500 mcg per administration, and thymosin beta-4 protocol summaries on 2–2.5 mg per administration with a lower administration frequency. No published trial defines a combined-vial protocol, so the combined figures shown reflect laboratory convention rather than any study result.

Why is the ratio fixed at 1:1?

Because both peptides are lyophilised into the same vial, the proportion cannot be varied after reconstitution — every draw supplies equal masses of each. Researchers who need independent ratios generally work with separate vials of each compound.

How stable is the reconstituted solution?

Once mixed with bacteriostatic water, the solution remains stable for up to 28 days when refrigerated at 2–8 °C and protected from light. Lyophilised vials are best stored at -20 °C.

Is this product for human use?

No. All AKH BioLabs products are supplied strictly for laboratory research. They are not approved for human consumption, and nothing on this page is medical advice.

Who tests this product?

A named laboratory outside AKH, on a report ordered by our manufacturer. The laboratory verification section on this page publishes that Certificate unaltered, or shows "Certificate pending" until a matching report has been published.

Popular

Recovery· Popular

In stock

TB-500 + BPC-157

Name: TB-500 + BPC-157
Brand: AKH BioLabs
SKU: tb-500-plus-bpc-157
Price: 113 USD
Availability: InStock

Dual Recovery Peptide Blend

TB-500 and BPC-157 are supplied as a 10mg + 10mg lyophilised blend for laboratory research. Price is shown in your currency, and its Certificate from a named outside laboratory is published on this page. Not for human or veterinary use.

Size10mg + 10mgPurity99.55%

A single-vial pairing of the two most studied compounds in connective-tissue recovery research. BPC-157 is investigated for angiogenesis and signalling at sites of damage; TB-500 (Thymosin Beta-4) is investigated for cell migration and actin regulation. The combination allows researchers to study complementary repair pathways in one reconstitution.

€100

Quantity

HPLC verified

9–14 day shipping

Full COA

Worldwide delivery

About this compound

The research profile.

This vial pairs two peptides that appear together throughout the tissue-repair literature: 10 mg of TB-500 (synthetic thymosin beta-4 chemistry) and 10 mg of BPC-157, for a combined 20 mg of lyophilised material. The two are unrelated molecules with separate published mechanisms, which is why they are studied side by side rather than as a single agent.

TB-500 chemistry derives from thymosin beta-4, the principal G-actin sequestering peptide in mammalian cells; published work describes effects on actin dynamics, cell migration, and angiogenesis in dermal and cardiac injury models. BPC-157 is a pentadecapeptide from a protective protein in gastric juice, studied for fibroblast outgrowth, cell survival under stress, and vascular recruitment in tendon, ligament, and gastrointestinal models.

Because the two act on different pathways — actin regulation on one side, growth-factor receptor expression and nitric-oxide signalling on the other — comparative work treats them as complementary rather than interchangeable. No published trial has established a combined-vial protocol; the literature cited here reports each peptide separately.

Published research

8 peer-reviewed studies on TB-500 + BPC-157 are summarised in our research library, including 5 published since 2023 — with study designs, reported findings and what the evidence does not establish.

Read the TB-500 + BPC-157 evidence base

For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.

Categorised as Recovery — Peptides studied in tissue-repair and inflammation models.

Dosing at a glance

What the literature reports.

For research and laboratory use only. Not for human consumption.

Route

Subcutaneous

Frequency

Once daily (combined draw)

Reported range

0.5–1.5 mg

Protocol duration

4–6 weeks

0.5 mgcombined mass per administration1.5 mg

The two peptides are cited separately in the literature: BPC-157 research protocols centre on roughly 200–500 mcg per administration once or twice daily, while thymosin beta-4 protocol summaries describe 2–2.5 mg per administration on a twice-weekly loading schedule. Because a combined vial fixes the ratio at 1:1, any single draw supplies half its mass as each component — the calculator shows that split for whatever combined amount is entered.

Ranges reflect protocols reported in the published literature on TB-500 + BPC-157 — see research citations.

Calculate a dilution

Reconstitution & storage

From powder to solution.

Step 01
Add 3 ml bacteriostatic water
Aim the stream at the vial wall rather than the powder.
Step 02
Swirl gently — never shake
Rotate the vial until the solution runs clear. Agitation degrades the peptide.
Step 03
Refrigerate at 2–8 °C
Reconstituted vials belong in the fridge, protected from direct light.
Step 04
Use within 28 days
Discard any remainder once the stability window closes.

Lyophilised · −20 °CReconstituted · 2–8 °C, 28 days

A 20 mg combined vial in 3 ml gives roughly 6.67 mg/ml total, split evenly between the two peptides. Refrigerate at 2–8 °C and protect from light.

Reconstitution calculator

20 mg vial

Vial amount

Bacteriostatic water

Amount per draw

1 mg = 1000 mcg

Draw

15units · U-100 insulin syringe

Concentration: 6.67 mg/ml
Draws per vial: 20
Cost per draw: €5.00

A draw at this setting contains approximately 0.5 mg TB-500 · 0.5 mg BPC-157.

For research and laboratory use only. Not for human consumption.

Laboratory arithmetic for TB-500 + BPC-157 — enter the COA-verified vial content for exact figures. Not medical advice.

Open the full calculator for this vial

Effect timeline

Observed across the research window.

Milestones summarise findings reported in the cited studies. Outcomes vary across models and protocols.

Start

Early cellular response

Studies of each peptide report early fibroblast and endothelial cell migration within the first days of administration in their respective injury models.

Week 2

Vascular and granulation measures

Vessel recruitment is described in BPC-157 work over the second week, while dermal thymosin beta-4 models report angiogenesis and collagen deposition across a similar window.

Week 4

Structural measures

Tendon studies report improved explant outgrowth at the one-month mark, and cardiac work reports raised integrin-linked kinase and Akt activity several weeks into treatment.

Week 6

Protocol end points

Published protocols for both peptides typically conclude in the 4–6 week window, where treated groups are compared against controls.

Start

Early cellular response

Studies of each peptide report early fibroblast and endothelial cell migration within the first days of administration in their respective injury models.

Week 2

Vascular and granulation measures

Vessel recruitment is described in BPC-157 work over the second week, while dermal thymosin beta-4 models report angiogenesis and collagen deposition across a similar window.

Week 4

Structural measures

Tendon studies report improved explant outgrowth at the one-month mark, and cardiac work reports raised integrin-linked kinase and Akt activity several weeks into treatment.

Week 6

Protocol end points

Published protocols for both peptides typically conclude in the 4–6 week window, where treated groups are compared against controls.

For research and laboratory use only. Not for human consumption.

Scientific research

The published evidence.

The dosing ranges and timeline milestones on this page summarise the peer-reviewed publications below.

References

01
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011). PubMed · 21030672
02
Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des (2018). PubMed · 29879879
03
Thymosin beta4 accelerates wound healing. J Invest Dermatol (1999). PubMed · 10469335
04
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004). PubMed · 15565145
05
Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med (2005). PubMed · 16099219

Laboratory verification

One Certificate, published unaltered.

The Certificate is a test report from a named laboratory outside AKH, ordered by our manufacturer and shown here exactly as the laboratory issued it. A printed copy ships in every parcel.

Batch: 26150
Test date: 29 Jul 2026
Task ID: #1812446
Purity: 99.55%

Verified by Brown Institute of Biomolecular Research. Scan the full report for every measurement.

Product FAQ